Filing Details
- Accession Number:
- 0001104659-23-074399
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2023-06-23 20:01:27
- Reporting Period:
- 2023-06-20
- Accepted Time:
- 2023-06-23 20:01:27
- Original Submission Date:
- 2023-06-22
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1023024 | Ani Pharmaceuticals Inc | ANIP | Pharmaceutical Preparations (2834) | 582301143 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1870913 | Muthusamy Shanmugam | C/O Ani Pharmaceuticals, Inc. 210 Main Street West Baudette MN 56623 | Head Of R&D, Coo-Novitium Ops | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2023-06-20 | 14,657 | $51.93 | 1,317,963 | No | 4 | S | Indirect | Held by Esjay LLC |
| Common Stock | Disposition | 2023-06-21 | 11,843 | $51.95 | 1,306,120 | No | 4 | S | Indirect | Held by Esjay LLC |
| Common Stock | Disposition | 2023-06-22 | 13,500 | $51.38 | 1,292,620 | No | 4 | S | Indirect | Held by Esjay LLC |
| Common Stock | Disposition | 2023-06-23 | 10,000 | $51.49 | 1,282,620 | No | 4 | S | Indirect | Held by Esjay LLC |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Indirect | Held by Esjay LLC |
| No | 4 | S | Indirect | Held by Esjay LLC |
| No | 4 | S | Indirect | Held by Esjay LLC |
| No | 4 | S | Indirect | Held by Esjay LLC |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 47,407 | Direct | |
| Common Stock | 5,000 | Indirect | Held by SS Pharma LLC |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $50.63 to $52.80, inclusive. The reporting person undertakes to provide to ANIPharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 4, 5 and 6 to this Form 4.
- The reporting person holds voting and dispositive power over the shares held by Esjay LLC.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $51.13 to $52.56, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $50.85 to $51.84, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $50.99 to $52.08, inclusive.
- The reporting person holds voting and dispositive power over the shares held by SS Pharma LLC.
Billionaire Hedge Funds
